Immunological and virological effects of structured treatment interruptions following exposure to hydroxyurea plus didanosine

AIDS Research and Human Retroviruses

Volumn 22, Issue 8, 2006, Pages 734-743

  Benito, José Miguel ^a   López, Mariola ^a   Ballesteros, Celia ^a   Lozano, Sara ^a   Capa, Laura ^a   Barreiro, Pablo ^a   Sempere, José ^b   Gonzalez Lahoz, Juan ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSITY OF ALICANTE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD45RO ANTIGEN; DIDANOSINE; GAG PROTEIN; GAMMA INTERFERON; HYDROXYUREA; NEF PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD38 ANTIGEN;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; REBOUND; STATISTICAL ANALYSIS; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; BLOOD; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHI SQUARE DISTRIBUTION; DRUG COMBINATION; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; METHODOLOGY; MIDDLE AGED; REGRESSION ANALYSIS;

ADULT; ANTI-HIV AGENTS; ANTIGENS, CD38; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHI-SQUARE DISTRIBUTION; DIDANOSINE; DRUG THERAPY, COMBINATION; FEMALE; GENE PRODUCTS, NEF; HIV INFECTIONS; HUMANS; HYDROXYUREA; IMMUNITY, CELLULAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RNA, VIRAL;

EID: 33748755278     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.734     Document Type: Article

References (41)

1. Yeni P, Hammer S, Carpenter C, et al.: Antiretroviral treatment for adult HIV infection in 2002. JAMA 2002;288:222-235.
2. Gulick R, Mellors J, Havlir D, et al.: Three-year suppression of HIV viremia with indinavir, zidovudine and lamivudine. Ann Intern Med 2000;133:35-39.
3. Staszewski S, Morales-Ramirez J, Tashima K, et al.: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection adults. N Engl J Med 1999;341:1865-1873.
4. Carr A and Cooper D: Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-1430.
5. Saag M, Powderly W, and Schambelan M: Switching antiretroviral drugs for treatment of metabolic complications in HIV-1 infection. Top HIV Med 2002;10:47-51.
6. Stone V, Hogan J, Schuman A, et al.: Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens. J Acquir Immune Defic Syndr 2001;28:124-131.
7. Valdez H: Immune restoration after treatment of HIV-1 infection with highly active antiretroviral therapy (HAART). AIDS Rev 2002;4:157-164.
8. Nuñez M, Barreiro P, and Soriano V: Simplifying antiretroviral therapy. AIDS Rev 2000;2:93-99.
9. Dybul M, Chun T, Yoder C, et al.: Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci USA 2001;98:15161-15166.
10. Zala C, Rouleau D, and Montaner JS: Role of hydroxyurea in the treatment of disease due to human immunodeficiency virus infection. Clin Infect Dis 2000;30(Suppl. 2):143-150.
11. Barreiro P, De Mendoza C, Camino N, et al.: Hydroxyurea plus didanosine as maintenance therapy for HIV- infected patients on long- term successful highly active antiretroviral therapy. HIV Clin Trials 2003;4:361-371.
12. Frank I, Bosch R, Fiscus S, et al.: Activity, safety and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: A randomised, placebo-controlled trial, ACTG 307. AIDS Res Hum Retroviruses 2004;20:916-926.
13. Lori F, Malykh A, Cara A, et al.: Hydroxyurea as an inhibitor of HIV type 1 replication. Science 1994;266:801-805.
14. Lori F, Jessen H, Foli A, et al.: Long-term suppression of HIV-1 by hydroxyurea and didanosine. JAMA 1997;277:1437-1438.
15. Lori F, Jessen H, Lieberman J, et al.: Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir). AIDS Res Hum Retroviruses 1999;15: 619-624.
16. Galpin J, Globe D, and Casciato D: Safety, sheltering & synergy of hydroxyurea (HU) with ddI or ddI plus d4T in HIV-infected patients. Fifth Conference on retroviruses and opportunistic infections. Chicago, February 1998. Abstract 654.
17. Lori F, Rosenberg E, Lieberman J, et al.: Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters. AIDS Res Hum Retroviruses 1999; 15:1133-1138.
18. López M, Benito JM, Lozano S, et al.: Enhanced HIV-specific immune responses in chronically HIV infected patients receiving didanosine (ddI) plus hydroxyurea. AIDS 2004;18:1251-1261.
19. DOfizzi G, Montesano C, Agrati C, et al.: Expansion of pre-terminally differentiated CD8 T cells in chronic HIV-positive patients presenting a rapid viral rebound after structured treatment interruption. AIDS 2002;16:2431-2438.
20. Oxenius A, Price D, Gunthard H, et al.: Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci USA 2002;99:13747-13752.
21. Papasavvas E, Ortiz G, Gross R, et al.: Enhancement of HIV type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis 2000; 182:766-775.
22. Ruiz L, Carcelain G, Martinez-Picado J, et al.: HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 2001;15:F19-27.
23. Garcia F, Plana M, Ortiz G, et al.: The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001;15:F29-40.
24. Lawrence J, Mayers D, Hullsiek K, et al.: Structured treatment interruption in patients with multidrug-resistant HIV. N Engl J Med 2003;349:837-846.
25. Papasavvas E, Kostman J, Mounzer K, et al.: Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLos Med 2004;1:e64.
26. Ruiz L, Ribera E, Bonjoch A, et al.: Role of structured treatment interruption before a 5-drug salvage regimen: The Retrogene study. J Infect Dis 2003;88:977-985.
27. 3. J Acquir Immune Defic Syndr 2004;36:791-799.
28. Moss R, Brandt C, Giermakowska W, et al.: HIV-specific immunity during structured antiviral drug treatment interruption. Vaccine 2003;21:1066-1071.
29. Rosenberg E, Altfeld M, Poon S, et al.: Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-526.
30. Hess C, Altfeld M, Thomas S, et al.: HIV-specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet 2004;363:833-834.
31. Alexander T, Ortiz G, Wellons M, et al.: Changes in CD4 T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. J Acquir Immune Defic Syndr 2003;34:475-481.
32. Metzner KJ, Bonhoeffer S, Fischer M, et al.: Emergence of minor populations of HIV type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 2003;188:1433-1443.
33. Cao J, McNevin J, Holte S, et al.: Comprehensive analysis of HIV-specific IFN-g-secreting CD8+ T cells in primary HIV infection. J Virol 2003;77:6867-6875.
34. Ali A, Pillai S, Ng H, et al.: Broadly increased sensitivity to cytotoxic T lymphocytes resulting from Nef epitope escape mutants. J Immunol 2003;171:3999-4005.
35. Carcelain G, Tubiana R, Samri A, et al.: Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J Virol 2001;75:234-241.
36. Binley J, Schiller D, Ortiz G, et al.: The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. J Infect Dis 2000;181:1249-1263.
37. Benito JM, Lopez M, Lozano S, et al.: CD38 expression on CD8+ lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy. AIDS Res Hum Retroviruses 2003;20:227-233.
38. Gougeon ML, Lecouer H, Dulioust A, et al.: Programmed cell death in peripheral lymphocytes from HIV-infected persons: Increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol 1996;156:3509-3520.
39. Benito JM, Lopez M, Lozano S, et al.: Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005;38:373-381.
40. Bofill M, Mocroft A, Lipman M, et al.: Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS 1996;10: 827-834.
41. Foli A, Maserati R, Barasolo G, et al.: Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during strutured treatment interruptions. Antiviral Ther 2004;9: 123-132.